

**GIUSEPPE NOCENTINI**

**SCIENTIFIC CURRICULUM**

## **GIUSEPPE NOCENTINI**

Work Address: University of Perugia - Department of Medicine – Section of Pharmacology,  
Piazza Severi 1, I-06129 Perugia, ITALY

ORCID 0000-0002-5209-0488

ResearcherId B-9412-2013

Telephone: +39 0755858115

E-mail: [giuseppe.nocentini@unipg.it](mailto:giuseppe.nocentini@unipg.it)

Nationality: Italian

Date of birth: 6 February 1961

Place of birth: Forlì, ITALY

## **SCIENTIFIC ACTIVITY**

His first studies concerned the screening and characterization of experimental antitumor compounds with particular reference to ribonucleotide inhibitors. Then, he performed studies on glucocorticoid mechanism of action, through differential display and microarray techniques. Studies on the mechanism(s) of action of glucocorticoids are ongoing.

During his studies, he cloned and characterized Glucocorticoid-induced Tumor Necrosis Factor Receptor (TNFR) family related gene (GITR). GITR, which belongs to the TNFR superfamily, was shown, by his group, to be involved in activation and survival of effector T lymphocytes (CD4<sup>+</sup> and CD8<sup>+</sup>) and regulatory T lymphocytes (Treg) during the immune/inflammatory response. Some mouse models of pathologies demonstrated that GITR-derived signals in different T cell subpopulations contribute to the development of the immune/inflammatory response and control the onset and development of autoimmune and inflammatory diseases.

He first described a new Treg subset (GITRsp pTregs) in humans and its role in autoimmune diseases. He is presently studying the role of Tregs in tumors and human autoimmune diseases. In particular, he is investigating the potential role of GITR triggering in the treatment of autoimmune diseases and the underlying mechanisms.

He is also evaluating through bioinformatics the antitumoral and toxic effects of targeting Treg markers to elicit antibody-dependent cell cytotoxicity (ADCC).

## SCIENTIFIC COLLABORATIONS

During his studies, he established several national and international collaborations that led to publications in peer-reviewed international journals. Among them were set collaborations with the group led by Prof. Franchetti and Grifantini, University of Camerino; Prof. Goldstein, University of Rochester; Prof. Navarra and Preziosi, Catholic University of Medicine, Rome; Prof. Pandolfi, Memorial Sloan-Kettering Cancer Center, New York; Prof. Caputi and Cuzzocrea, University of Messina; Prof. Graziani, University of Tor Vergata; Prof. Gerli, University of Perugia; Prof. Bernardini and Cantarella, University of Catania; Dr. O'Keeffe, University of Cork; Prof. Shimizu, University of Kyoto.

## SCIENTIFIC SOCIETY

2000-present, member of “Italian Society of Pharmacology”

2017-present, member of “European Academy of Sciences and Arts.”

2017-present, member of “European Academy of Allergy and Clinical Immunology.”

## PUBLICATIONS AND METRICS

Ninety publications in peer-reviewed international journals, 3 chapters in scientific books, 1 item in an electronic encyclopedia. In the top 16 publications published by Nocentini, he is first author of 7 manuscript, co-first author of 5 manuscripts, corresponding author in 2 manuscripts, last author of 1 manuscript. In the studies, reviews, commentary, and a book chapter published in the last 10 years (2008-2017), Nocentini is first author of 10 manuscripts, co-first author of 4 manuscripts, corresponding author in 5 manuscripts, last author of 1 manuscript

Five chapters in Italian books of Pharmacology for University students.

Translation into Italian of some sections of the Merck manual.

Nine gene sequences published in the NCBI databank.

About 50 informative articles published in “SIF Farmaci in evidenza.”

**Total citations:** 2725 and 3909 according to Web of Science and Google Scholar, respectively

**H-index:** 29 and 32 according to Web of Science and Google Scholar, respectively

Number of studies in the last 10 years: 41

Citation in the last 15 years: 1973 (according to Web of Science and Scopus combined)

H-index in the last 15 years: 25 (according to Web of Science and Scopus combined)

H-index from 2013: 22 according to Google Scholar

### **INVITED SPEAKER**

He has been invited speaker at 3 national congresses, 5 local congresses and meetings, 11 ECM and courses. He has been chairperson at 3 national congresses

### **OTHER SCIENTIFIC ACTIVITY**

- He is has been a reviewer for several international journals, including British Journal Pharmacology, European Journal of Immunology, Journal Pharmacology and Experimental Therapeutics, CNS Neuroscience & Therapeutics, Cell Death and Disease, PLOSone and Oncoimmunology.
- 2016-2017, Editor in Chief of the American Journal of Pharmacology and Toxicology
- 2017-present, Associate Editor of PeerJ.
- He participated to an Eli-Lilli board and was an Amgen Consultant.

### **Scientific Publications**

- 1. G. Cristalli, P. Franchetti, M. Grifantini, G. Nocentini, and S. Vittori**  
3,7-Dideazapurine nucleosides. Synthesis and antitumor activity of 1-deazatubercidin and 2-chloro-2'-deoxy-3,7-dideazaadenosine  
J. Med. Chem. 1989, 32: 1463-1466.  
**I.F. 4,802**
- 2. A. Barzi, E. Lepri, E. Menconi, G. Nocentini, M. Liberati, A. Santucci, and M. Schippa**  
A 4-day chemosensitivity assay in vitro reliably predicts clinical response of patients with acute leukemia  
Haematologica (presently "Haematologica-The Hematology Journal") 1989, 74: 449-454.  
**I.F. 6,416**
- 3. G. Nocentini, E. Lepri, A. Di Giovanni, F. Federici, P. Franchetti, and A. Barzi**  
Valutazione in vitro dello spettro di attività antitumorale di un potenziale inibitore della ribonucleotide reduttasi  
J. Chemotherapy, 1990, Supplemento 2: 566-568.  
**I.F. 0,922**
- 4. G. Nocentini, A. Barzi, and P. Franchetti**

Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase  
Cancer Chemoth. Pharm. 1990, 26(5): 345-351.

**I.F. 2,654**

**5. P. Franchetti, G. Cristalli, M. Grifantini, L. Cappellacci, S. Vittori, and G. Nocentini**  
Synthesis and antitumor activity of 2- $\beta$ -D-ribofuranosyloxazole-4-carboxamide (oxazofurin)  
J. Med. Chem. 1990, 33(10): 2849-2852.

**I.F. 4,802**

**6. G. Nocentini, F. Federici, R. Armellini, P. Franchetti, and A. Barzi**  
Isolation of two cellular lines resistant to ribonucleotide reductase inhibitors to investigate the inhibitory activity of 2,2'-bipyridyl-6-carbothioamide  
Anti-Cancer Drug 1990, 1(2): 171-177.

**I.F. 2,230**

**7. P. Franchetti, L. Cappellacci, G. Cristalli, M. Grifantini, A. Pani, P. La Colla, and G. Nocentini**  
Synthesis and evaluation of anti-HIV-1 and antitumor activity of 2',3'-dideoxy-2',3'-dideoxy-3-deazaadenosine and some 2',3'-dideoxy-3-deazaadenosine and some 2',3'-dideoxy-3-deazaadenosine 5'-dialkyl phosphates  
Nucleosides Nucleotides 1991, 10(7): 1551-1562.

**I.F. 0,723**

**8. P. Franchetti, L. Cappellacci, M. Grifantini, G. Lupidi, G. Nocentini, and A. Barzi**  
8-aza analogues of deaza purine nucleosides. 1. synthesis and biological evaluation of 8-aza-1-deazaadenosine and 2'-deoxy-8-aza-1-deazaadenosine  
Nucleosides Nucleotides 1992, 11(5): 1059-1076.

**I.F. 0,723**

**9. G. Nocentini, F. Federici, P. Franchetti, and A. Barzi**  
2,2'-bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit  
Cancer Res. 1993, 53(1): 19-26.

**I.F. 7,543**

**10. G. Migliorati, I. Nicoletti, G. Nocentini, M. C. Pagliacci, and C. Riccardi**  
Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes  
Pharmacol. Res. 1994, 30(1): 43-52

**I.F. 3,929**

**11. G. Nocentini, S. Ronchetti, A. Bartoli, G. Testa, F. D'Adamio, C. Riccardi, and G. Migliorati**  
T cell receptor  $\tau$  an alternatively spliced product of the T cell receptor  $\zeta$  gene  
Eur. J. Immunol 1995, 25: 1405-1409.

**I.F. 5,179**

**12.** L. Savini, P. Massarelli, L. Chiasserini, A. Segà, C. Pellerano, A. Barzi, and **G. Nocentini**  
Chelating agents as potential antitumorals: 2-quinolylylhydrazones and bis-2-quinolylylhydrazones  
Eur. J. Med. Chem. 1995, 30: 547-552.

**I.F. 2,301**

**13.** **G. Nocentini**, E. Castagnino, A. Salvatori, S. Corsano, and M. C. Fioretti  
In vitro evaluation of the potential antitumor activity of an N-Acridyl-pentanoyloxypyridine-2-thione derivative  
Arzneimittel-Forschung/Drug Res. 1995, 45(II), 10: 1127-1130.

**I.F. 0,692**

**14.** **G. Nocentini**, and A. Barzi  
A predictive screening model for in vitro selection of agents with potential antitumor activity  
Arzneimittel-Forschung/Drug Res. 1995, 45(II), 12: 1306-1311.

**I.F. 0,692**

**15.** L. Cappellacci, P. Franchetti, M. Grifantini, L. Messini, G. Abu Sheikha, **G. Nocentini**, R. Moraca, and B. M. Goldestein  
Synthesis, antitumor activity and crystallographic studies of analogues of tiazofurin.  
Nucleosides Nucleotides 1995, 14(3-5): 637-640.

**I.F. 0,723**

**16.** P. Franchetti, L. Cappellacci, M. Grifantini, A. Barzi, **G. Nocentini**, H. Yang, A. O'Connor, H. N. Jayaram, C. Carrell, and B. M. Goldstein  
Furanfuran and thiophenfuran: two novel tiazofurin analogues. Synthesis, structure, antitumor activity and interactions with IMP dehydrogenase  
J. Med. Chem. 1995, 38: 3829-3837.

**I.F. 4,802**

**17.** S. Ronchetti, **G. Nocentini**, L. Giunchi, A. Bartoli, G. Migliorati, and C. Riccardi  
RT-PCR used to study alternative spliced products of the TCR $\zeta$  gene locus  
Minerva Biotech. 1995, 7: 275-279.

**I.F. 0,167**

**18.** G. Migliorati, D. Delfino, **G. Nocentini**, I. Nicoletti, and C. Riccardi  
Tumor cell death induced through the receptor for interleukin-2  
Int. J. Immunopath. Ph. 1995, 8(3): 161-165.

**I.F. 3,061**

**19.** **G. Nocentini**, and A. Barzi  
The 2,2'-bipyridyl-6-carbothioamide copper (II) complex differs from the iron (II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity

Biochem. Pharmacol. 1996, 52: 65-71.

**I.F. 4,254**

**20.** G. Migliorati, A. Bartoli, **G. Nocentini**, S. Ronchetti, R. Moraca, C. Marchetti, and C. Riccardi

Dexamethasone modulates CD2 expression

Int. J. Immunopharmacol. (from January 2001 published with the title International Immunopharmacology) 1996, 18(12): 677-684.

**I.F. 2,066**

**21. G. Nocentini**<sup>\$</sup>

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy

Crit Rev Oncol Hemat 1996, 22, 89-126.

**I.F. 5,269**

\$ corresponding author

**22.** G. Migliorati, A. Bartoli, **G. Nocentini**, S. Ronchetti, R. Moraca, and C. Riccardi

Effect of Dexamethasone on T-cell receptor/CD3 expression in a hybridoma T-cell line

Mol. Cell. Biochem. 1997, 167 (1-2): 135-144.

**I.F. 1,707**

**23.** P. Navarra, U. Grohmann, **G. Nocentini**, G. Tringali, P. Puccetti, C. Riccardi, and P. Preziosi

Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines *in vivo*

J Pharmacol Exp Ther 1997, 280(1): 477-482.

**I.F. 4,093**

**24. G. Nocentini**, L. Giunchi, S. Ronchetti, L.T. Krausz, A. Bartoli, R. Moraca, G. Migliorati and C. Riccardi

A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis

P Natl Acad Sci USA 1997, 94(12): 6216-6221.

**I.F. 9,432**

**25.** S. Ronchetti\*, **G. Nocentini\***, L. Giunchi, A. Bartoli, R. Moraca, C. Riccardi, and G. Migliorati

Short-term dexamethasone treatment modulates the expression of the murine TCR $\zeta$  gene locus

Cell. Immunol. 1997, 178: 124-131.

**I.F. 2,698**

\* Equally contributed

**26.** B. Palumbo, L. Parnetti, **G. Nocentini**, L. Cardinali, S. Brancorsini, C. Riccardi, and U. Senin

Apolipoprotein E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients

Neurosci. Lett. 1997, 231: 59-61.

**I.F. 2,085**

**27. G. Nocentini**, and A. Barzi

Antitumor activity of 2,2'-bipyridyl-6-carbothioamide, a ribonucleotide reductase inhibitor.  
Gen Pharmacol (from January 2002 published with the title Vascular Pharmacology) 1997,  
29(5): 701-706.

**I.F. 2,044**

**28. G. Nocentini**, L. Giunchi, S. Ronchetti, A. Bartoli, G. Migliorati, and C. Riccardi

Glucocorticoids: regulation of gene expression and apoptosis  
J Chemotherapy 1998, 10(2): 187-191.

**I.F. 0,992**

**29. L. Giunchi\***, **G. Nocentini\***, S. Ronchetti, A. Bartoli, C. Riccardi and G. Migliorati

TCR $\kappa$ , a new splicing of the murine TCR $\zeta$  gene locus is modulated by glucocorticoid  
treatment

Mol. Cell. Biochem. 1999, 195: 47-53.

**I.F. 1,707**

\* Equally contributed

**30. O. Tabarrini**, V. Cecchetti, A. Fravolini, **G. Nocentini**, A. Barzi, S. Sabatini, M. Hua, and  
C. Sissi

Design and synthesis of modified quinolones as antitumoral acridones  
J. Med. Chem. 1999, 42(12): 2136-2144.

**I. F. 4,895**

**31. B. Palumbo**, D. Cadini, **G. Nocentini**, E. Filipponi, M.L. Fravolini, and U. Senin

Angiotensin converting enzyme deletion allele in different kinds of dementia disorders  
Neurosci. Lett. 1999, 267: 97-100.

**I.F. 2,085**

**32. G. Nocentini\***, A. Bartoli \*, S. Ronchetti, L. Giunchi, A. Cupelli, D. Delfino, G.  
Migliorati, and C. Riccardi

Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis  
factor/nerve growth factor receptor family  
DNA Cell Biol. 2000, 19(4): 207-219.

**I.F. 1,861**

\* Equally contributed

**33. G. Nocentini**, S. Ronchetti, A. Bartoli, S. Spinicelli, D. Delfino, L. Brunetti, G. Migliorati  
and C. Riccardi

Identification of three novel mRNA splice variants of GITR  
Cell Death Differ. 2000, 7 (4): 408-10.

**I.F. 8,240**



**34.** D.V. Delfino, M. Salcedo, B. Di Marco, E. Ayroldi, **G. Nocentini**, S. Bruscoli, L. Brunetti, H.-G. Ljunggren and C. Riccardi  
Differentiation of Ly49s-positive or -negative natural killer cells is inhibited by anti-H-2b monoclonal antibodies acting at the level of bone marrow progenitors from B6 mice  
Cell Growth Differ. (from September 2002 published with the title Mol Cancer Res) 2001, 12: 51-60.

**I.F. 4,162**

**35.** S. Ronchetti, **G. Nocentini**, C. Riccardi, and P.P.Pandolfi  
Role of GITR in activation response of T lymphocytes  
Blood 2002, 100:350-352.

**I.F. 10,555**

**36.** S. Spinicelli\*, **G. Nocentini\***, S. Ronchetti, L.T. Krausz, R. Bianchini, and C. Riccardi  
GITR interacts with the pro-apoptotic protein Siva and induces apoptosis  
Cell Death Differ 2002, 9(12):1382-4

**I.F. 8,240**

\* Equally contributed

**37.** M. Agostini, B. Di Marco, **G. Nocentini**, and D.V. Delfino  
Oxidative stress and apoptosis in immune diseases  
Inter J Immunopath Pharmacol 2002, 15(3):157-164

**I.F. 3,061**

**38.** T. Ingegneri, **G. Nocentini**, E. Mariani, L. Spazzafumo, C. Polidori, A. Cherubini, M. Catani, D. Cadini, U. Senin, and P. Mecocci  
Catepsin D polymorphism in italian elderly subjects with sporadic late onset Alzheimer's disease  
Dement Geriatr Cogn Disord 2003, 16(3):151-5.

**I.F. 2,641**

**39.** A. Vecchini, V. Ceccarelli, P. Orvietani, P. Caligiana, F. Susta, L. Binaglia, **G. Nocentini**, C. Riccardi, and P. Di Nardo  
Enhanced expression of hepatic lipogenic enzymes in an animal model of sedentariness.  
J Lipid Res. 2003, 44(4):696-704.

**I.F. 4,917**

**40.** A. Vecchini, V. Ceccarelli, F. Susta, P. Caligiana, P. Orvietani, L. Binaglia, **G. Nocentini**, C. Riccardi, G. Calviello, P. Paolozza, N. Maggiano and P. Di Nardo  
Dietary alfa-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells.  
J Lipid Res 2004, 45(2):308-316.

**I.F. 4,917**

**41.** S. Ronchetti, O. Zollo, S. Bruscoli, M. Agostini, R. Bianchini, **G. Nocentini**, E. Ayroldi and C. Riccardi.

GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.

Eur J Immunol. 2004, 34(3):613-22.

**I.F. 5,179**

**42.** S. Cuzzocrea, **G. Nocentini**, R. Di Paola, E. Mazzon, S. Ronchetti, T. Genovese, C. Muia, A.P. Caputi, C. Riccardi

Glucocorticoid-induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock.

J Leukocyte Biol 2004 76(5):933-40

**I.F. 4,403**

**43.** **G. Nocentini** and C. Riccardi

GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily

Eur J Immunol 2005, 35(4):1016-22.

**I.F. 5,179**

**44.** M. Agostini, E. Cenci, E. Pericolini, **G. Nocentini**, G. Bistoni, A. Vecchiarelli, C. Riccardi

The Glucocorticoid-Induced Tumor necrosis factor receptor-Related gene modulates the response to *Candida albicans* infection.

Infect Immun 2005, Nov;73(11):7502-8

**I.F. 3,996**

**45.** S. Cuzzocrea\*, **G. Nocentini\***, R. Di Paola, M. Agostini, E. Mazzon, S. Ronchetti, C. Crisafulli, E. Esposito, A.P. Caputi and C. Riccardi

Pro-inflammatory role of Glucocorticoid-Induced TNF receptor-Related gene in acute lung inflammation

J Immunol 2006, 177(1):631-41.

**I.F. 6,068**

\* Equally contributed

**46.** E Mariani, D Seripa, T Ingegni, **G Nocentini**, F Mangialasche, S Ercolani, A Cherubini, A Metastasio, A Pilotto, U Senin, P Mecocci.

Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease.

J Neurol Sci. 2006 Sep 25;247(2):187-91.

**I.F. 2,315**

**47.** R Bianchini\*, **G Nocentini\***, LT Krausz, K Fettucciari, S Coaccioli, S Ronchetti, C Riccardi.

Modulation of pro- and anti-apoptotic molecules in double positive (CD4+CD8+) thymocytes following dexamethasone treatment.

J Pharmacol Exp Ther. 2006 Nov;319(2):887-97.

**I.F. 4,003**

\* Equally contributed

**48.** S. Cuzzocrea, S. Ronchetti, T. Genovese, E. Mazzon, M. Agostini, R. Di Paola, E. Esposito, C. Muià, **G. Nocentini**, and C. Riccardi  
Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation.  
FASEB J 2007 Jan;21(1):117-29.

**I.F. 6,791**

**49. G. Nocentini**, S. Ronchetti, S. Cuzzocrea and C. Riccardi  
GITR/GITRL: more than an effector T cell co-stimulatory system  
Eur J Immunol 2007, May;37(5):1165-9.  
I.F. 5,179

**50.** L.T Krausz, R. Bianchini, S. Ronchetti, K. Fettuciari, **G. Nocentini**<sup>\$</sup> and C. Riccardi  
GITR-GITRL system, a novel player in shock and inflammation  
TheScientificWorldJournal 2007, May 1;7:533-66

**I.F. 1,658**

\$ corresponding author

**51.** Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, **Nocentini G**, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P.  
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.  
Nat Med 2007, May;13(5):579-86.

**I.F. 27,136**

**52. Nocentini G.**, Cuzzocrea S., Bianchini R., Mazzon E., Riccardi C.  
Modulation of acute and chronic inflammation of the lung by GITR and its ligand  
Ann NY Acad Sci 2007, 1107:380-391.

**I.F. 1,731**

**53.** Ronchetti S\*, **Nocentini G\***, Bianchini R, Krausz LT, Migliorati G, Riccardi C  
Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells.  
J Immunol 2007, Nov 1;179(9):5916-26.

**I.F. 5,646**

\* Equally contributed

**54.** Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, **Nocentini G**, Riccardi C.  
Peroxisome Proliferator-Activated Receptor- $\alpha$  Contributes to the Anti-Inflammatory Activity of Glucocorticoids  
Mol Pharmacol 2008, 73:323-337.

**I.F. 4,531**

**55. Nocentini G**, Cuzzocrea S, Genovese T, Bianchini R, Mazzon E, Ronchetti S, Esposito E, Di Paola R, Bramanti P and Riccardi C.

GITR-Fc fusion protein inhibits GITR triggering and protects from the inflammatory response following spinal cord injury.

Mol Pharmacol 2008, Jun;73(6):1610-1621.

**I.F. 4,531**

**56.** Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, **Nocentini G**, Cuzzocrea S, Graziani G.

Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.

Eur J Cancer 2008, Jun;44(9):1302-1314.

**I.F. 4,121**

**57. Nocentini G**, Riccardi C

GITR: a modulator of immune response and inflammation. In: Therapeutic targets of the Tumor Necrosis Factor Superfamily (editore Iqbal Grewal). 2009, Chapter 11, pages 156-173. Adv Exp Med Biol. 2009;647:156-73.

**I.F. 2,020**

**58.** Gerli R, **Nocentini G**, Alunno A, Bartoloni Bocci E, Bianchini R, Bistoni O, Riccardi C. Identification of regulatory T cells in systemic lupus erithematosus

Autoimmun Rev 2009, Mar;8(5):426-30

**I.F. 6,368**

**59.** Vecchiarelli A, Pericolini E, Gabrielli E, Agostini M, Bistoni F, **Nocentini G**, Cenci E, Riccardi C.

The GITRL-GITR system alters TLR-4 expression on DC during fungal infection.

Cell Immunol. 2009, 257(1-2):13-22

**I.F. 2,698**

**60.** Cantarella G, Di Benedetto G, Scollo M, Paterniti I, Cuzzocrea S, Bosco P, **Nocentini G**, Riccardi C, Bernardini R.

Neutralization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand reduces spinal cord injury damage in mice.

Neuropsychopharmacology. 2010 May; 35(6):1302-14.

**I.F. 6,835**

**61.** Alunno A, Bartoloni E, **Nocentini G**, Bistoni O, Ronchetti S, Petrillo MG, Riccardi C, Gerli R.

Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis.

Autoimmun Highlights 2010, 1:45-51

**62.** Alunno A, **Nocentini G**, Bistoni O, Bianchini R, Bartoloni Bocci E, Riccardi C, Gerli R.

Glucocorticoid-induced TNFR-related protein (GITR) come marker di cellule T regolatorie umane: espansione della sottopopolazione cellulare GITR+CD25- in pazienti affetti da lupus eritematoso sistemico.  
Reumatismo, 2010; 62(3):195-201.

**63.** Ronchetti S\*, **Nocentini G\***, Petrillo MG, Bianchini R, Sportoletti P, Bastianelli A, Ayroldi EM, Riccardi C.  
Glucocorticoid-Induced TNFR family Related gene (GITR) enhances dendritic cell activity.  
Immunol Lett. 2011 Mar 30;135(1-2):24-33.

**I.F. 2,906**

\* Equally contributed

**64.** Ceccarelli V, **Nocentini G**, Riccardi C, Ayroldi E, Di Nardo P, Roberti R, Binaglia L, Vecchini A.  
Effect of dietary saturated fatty acids on HNF-4 $\alpha$  DNA binding activity and ApoCIII mRNA in sedentary rat liver.  
Mol Cell Biochem. 2011 Jan;347(1-2):29-39.]

**I.F. 1,896**

**65.** Galuppo M\*, **Nocentini G\***, Mazzon E, Ronchetti S, Esposito E, Riccardi L, Sportoletti P, Di Paola R, Bruscoli S, Riccardi C and Cuzzocrea S  
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice.  
Brit J Pharmacol. 2011 Mar;162(5):1186-201.

**I.F. 5,204**

\* Equally contributed

**66.** Bianchini R, Bistoni O, Alunno A, Petrillo MG, Ronchetti S, Sportoletti P, Bocci EB, **Nocentini G<sup>§</sup>**, Gerli R, Riccardi C.  
CD4(+)CD25(low)GITR(+) cells: A novel human CD4(+) T-cell population with regulatory activity.  
Eur J Immunol. 2011 Aug;41(8):2269-78.

**I.F. 4,942**

§ corresponding author

**67.** Galuppo M\*, **Nocentini G\***, Mazzon E, Ronchetti S, Esposito E, Riccardi L, Di Paola R, Bruscoli S, Riccardi C, Cuzzocrea S.  
GITR Gene Deletion and GITR-Fc Soluble Protein Administration Inhibit Multiple Organ Failure Induced by Zymosan.  
Shock. 2011 Sep;36(3):263-71.

**I.F. 3,203**

\* Equally contributed

**68.** Ceccarelli V, Racanicchi S, Martelli MP, **Nocentini G**, Fettucciari K, Riccardi C, Marconi P, Di Nardo P, Grignani F, Binaglia L, Vecchini A.

Eicosapentaenoic acid demethylates a single CpG that mediates the expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells.  
J Biol Chem. 2011 Aug 5;286(31):27092-102. Epub 2011 Jun 9.

**I.F. 5,328**

**69. Nocentini G**, Ronchetti S, Petrillo MG, Riccardi C.  
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.  
Br J Pharmacol. 2012 Apr;165(7):2089-99. doi: 10.1111/j.1476-5381.2011.01753.x.

**I.F. 5,2**

**70. Ronchetti S\***, **Nocentini G\***, Petrillo MG, Riccardi C.  
CD8+ T cells: GITR matters.  
ScientificWorldJournal. 2012;2012:308265. Epub 2012 Apr 30.

**I.F. 1,65**

\* Joint first authors

**71. Alunno A**, Bartoloni E, Bistoni O, **Nocentini G**, Ronchetti S, Caterbi S, Valentini V, Riccardi C, Gerli R.  
Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New.  
Clin Dev Immunol. 2012;2012:823085. Epub 2012 Jun 14.

**72. Laura McKelvey**, Humberto Gutierrez, **Giuseppe Nocentini**, Sean J. Crampton, Alun M. Davies, Carlo R. Riccardi, and Gerard W. O'keeffe.  
The intracellular portion of GITR enhances NGF-promoted neurite growth through an inverse modulation of Erk and NF- $\kappa$ B signaling.  
Biology Open 2012 1:1016-1023

**73. Ayroldi E**, Cannarile L, Migliorati G, **Nocentini G**, Delfino DV, Riccardi C.  
Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways.  
FASEB J. 2012 Dec;26(12):4805-20. doi: 10.1096/fj.12-216382. Epub 2012 Sep 5.

**I.F. 5,71**

**74. Alunno A**, **Nocentini G**, Bistoni O, Petrillo MG, Bartoloni Bocci E, Ronchetti S, Lo Vaglio E, Riccardi C, Gerli R.  
Expansion of CD4+CD25-GITR+ regulatory T-cell subset in the peripheral blood of patients with primary Sjögren's syndrome: correlation with disease activity.  
Reumatismo. 2012 Dec 11;64(5):293-8. doi: 10.4081/reumatismo.2012.293.

**75. Alunno A**, Maria Grazia Petrillo, **Giuseppe Nocentini**, Onelia Bistoni, Elena Bartoloni, Sara Caterbi, Rodolfo Bianchini, Chiara Baldini, Ildo Nicoletti, Carlo Riccardi, Roberto Gerli.  
Characterization of a new regulatory CD4+ T-cell subset in primary Sjögren's syndrome.  
Rheumatology (Oxford). 2013 Aug;52(8):1387-96. doi: 10.1093/rheumatology/ket179. Epub 2013 May 14.

**I.F. 4,06**

**76.** Lacal PM, Petrillo MG, Ruffini F, Muzi A, Bianchini R, Ronchetti S, Migliorati G, Riccardi C, Graziani G, **Nocentini G**.

Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion.

J Pharmacol Exp Ther. 2013 Oct;347(1):164-72. doi: 10.1124/jpet.113.207605. Epub 2013 Jul 26.

**I.F. 4,003**

**77.** Krausz LT, Major ZZ, Muresanu DF, Chelaru E, Nocentini G\*, Riccardi C\*.

Characterization of CD4+ and CD8+ Tregs in a Hodgkin's lymphoma patient presenting with myasthenia-like symptoms.

Ideggyogy Sz 2013 66(9-10):343-348.

**I.F. 0,348**

\* Joint senior authors

**78.** Ceccarelli V, **Nocentini G**, Billi M, Racanicchi S, Riccardi C, Roberti R, Grignani F, Binaglia L, Vecchini A.

Eicosapentaenoic acid activates RAS/ERK/C/EBP $\beta$  pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells.

PLoS One. 2014 Jan 13;9(1):e85025. doi: 10.1371/journal.pone.0085025. eCollection 2014.

**I.F. 3.534**

**79.** Petrillo MG, Fettucciari K, Montuschi P, Ronchetti S, Cari L, Migliorati G, Mazzon E, Bereshchenko O, Bruscoli S, **Nocentini G**<sup>\$</sup>, Riccardi C.

Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids.

BMC Pharmacol Toxicol. 2014 Jul 3;15:35. doi: 10.1186/2050-6511-15-35.

**I.F. 1.842**

\$ corresponding author

**80.** **Nocentini G**, Alunno A, Petrillo M, Bistoni O, Bartoloni E, Caterbi S, Ronchetti S, Migliorati G, Riccardi C, Gerli R.

Expansion of regulatory G $\text{ITR}^+$ CD25<sup>low/-</sup>CD4<sup>+</sup> T cells in systemic lupus erythematosus patients.

Arthritis Res Ther. 2014 Sep 26;16(5):444.

**I.F. 4.117**

**81.** Ayroldi E, Petrillo MG, Bastianelli A, Marchetti MC, Ronchetti S, **Nocentini G**, Ricciotti L, Cannarile L, Riccardi C.

L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells.

Cell Death Differ. 2015 Jan;22(1):118-30. doi: 10.1038/cdd.2014.129.

**I.F. 8.385**

**82.** Petrillo MG, Ronchetti S, Ricci E, Alunno A, Gerli R, **Nocentini G**<sup>\$</sup>, Riccardi C.  
GITR+ regulatory T cells in the treatment of autoimmune diseases.  
Autoimmunity Reviews, 2015, Feb;14(2):117-26  
\$ Corresponding author

**I.F. 7.933**

**83.** Simona Ronchetti\*, Erika Ricci\*, Maria Grazia Petrillo, Luigi Cari, Graziella Migliorati, **Giuseppe Nocentini**<sup>\$</sup>, Carlo Riccardi  
Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.  
J Immunol Res, 2015. 2015:171520. doi: 10.1155/2015/171520.  
\$ Corresponding author

**84.** **Giuseppe Nocentini**, Graziella Migliorati and Carlo Riccardi  
The Molecular and Cellular Mechanisms Responsible for the Anti-inflammatory and Immunosuppressive Effects of Glucocorticoids  
R. Cimaz (ed.), Systemic Corticosteroids for Inflammatory Disorders in Pediatrics. 2015.  
Springer International Publishing Switzerland 2015  
DOI 10.1007/978-3-319-16056-6\_4

**85.** **Giuseppe Nocentini**, Simona Ronchetti, Stefano Bruscoli and Carlo Riccardi  
The Clinical Pharmacology of Past, Present, and Future Glucocorticoids.  
R. Cimaz (ed.), Systemic Corticosteroids for Inflammatory Disorders in Pediatrics.  
Springer International Publishing Switzerland 2015  
DOI 10.1007/978-3-319-16056-6\_5

**86.** Cari L, Ricci E, Gentili M, Petrillo MG, Ayroldi E, Ronchetti S, **Nocentini G**, Riccardi C.  
A focused Real Time PCR strategy to determine GILZ expression in mouse tissues.  
Results Immunol. 2015 Oct 21;5:37-42. doi: 10.1016/j.rinim.2015.10.003. eCollection 2015.

**87.** **Nocentini G**, Migliorati G, Riccardi C  
Are we able to harness the immunomodulatory power of cytokines for novel autoimmune disease treatments?  
American Journal of Pharmacology and Toxicology 2015 10 (2), pp. 37-39

**88.** **Nocentini G**<sup>\$</sup>, Cari L, Ronchetti S, Riccardi C<sup>\$</sup>.  
Modulation of tumour immunity: a patent evaluation of WO2015026684A1.  
Expert Opin Ther Pat. 2016;26(3):417-25.

**I.F. 4.297**

\$ Corresponding authors

**89.** **Nocentini G**, Cari L and Riccardi C  
GITR: A Modulator of Regulatory and Effector T-cell Activity, Crucial in Tumour Rejection and Autoimmune Diseases



In eLS, John Wiley & Sons Ltd, Chichester (2017)

**90. Giuseppe Nocentini**, Luigi Cari, Graziella Migliorati, & Carlo Riccardi  
The role of GITR single-positive cells in immune homeostasis  
Immunity, Inflammation and Disease 2017; 5(1): 4–6

**91.** Di Benedetto G, Saccone S, Lempereur L, Ronsisvalle N, **Nocentini G**, Bianchini R, Riccardi C, Bernardini R, Cantarella G.  
The proinflammatory cytokine GITRL contributes to TRAIL-mediated neurotoxicity in the HCN-2 human neuronal cell line.  
Curr Alzheimer Res. 2017 May 18. doi: 10.2174/1567205014666170519113912. [Epub ahead of print]

**I.F. 3.145**

**92.** Vienna Ludovini, Cinzia Antognelli, Antonio Rulli, Jennifer Foglietta, Lorenza Pistola, Rulli Eliana, Irene Floriani, **Giuseppe Nocentini**, Francesca Romana Tofanetti, Simonetta Piattoni, Elisa Minenza, Vincenzo Nicola Talesa, Angelo Sidoni, Maurizio Tonato, Lucio Crinò and Stefania Gori

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.

BMC Cancer (2017) 17:502

DOI 10.1186/s12885-017-3483-2

**I.F. 3.288**

**93.** Luigi Cari, **Giuseppe Nocentini**<sup>§</sup>, Graziella Migliorati, Carlo Riccardi  
Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis  
OncoImmunology. 2017 Nov 9;7(2):e1387705. doi: 10.1080/2162402X.2017.1387705.  
eCollection 2018.

**I.F. 7.719**

§ Corresponding authors

**94. Nocentini, Giuseppe**; Cari, Luigi; Migliorati, Graziella; Riccardi, Carlo  
Treatment of autoimmune diseases and prevention of transplant rejection/graft-versus-host disease by regulatory T cells: The state of the art and perspectives (Chapter 16).  
Rongxin Zhang and Trygve Tollefsbol (eds.) The Epigenetics of Autoimmunity  
ISBN: 9780128099124, in press.

Giuseppe Nocentini



Giuseppe Nocentini  
Dipartimento di Medicina  
Sezione di Farmacologia  
Piazzale Severi  
Tel: 075 5858115  
E-mail: [giuseppe.nocentini@unipg.it](mailto:giuseppe.nocentini@unipg.it)